Parthipan Milothy, Feng Gregory, Toledano Nelly, Donison Valentina, Breunis Henriette, Sudharshan Abirami, Emmenegger Urban, Finelli Antonio, Warde Padraig, Soto-Perez-de-Celis Enrique, Krzyzanowska Monika, Matthew Andrew, Clarke Hance, Mina Daniel Santa, Alibhai Shabbir M H, Puts Martine
Department of Medicine, University Health Network, Toronto, Canada.
Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.
J Geriatr Oncol. 2023 Jan;14(1):101397. doi: 10.1016/j.jgo.2022.10.012. Epub 2022 Oct 28.
Exploring symptom experiences of older men during metastatic prostate cancer treatment can help clinicians identify unmet supportive care needs that, if addressed, could improve toxicity management and enhance patient wellbeing. Previous qualitative studies of older adults with advanced prostate cancer have focused on the psychological experience rather than the overall symptom experience. Therefore, the objective of this study was to understand the lived experience of symptoms and supportive care needs in older men undergoing treatment for metastatic prostate cancer.
Semi-structured interviews were conducted with older adults (aged 65+) who completed their first cycle of chemotherapy, androgen-axis targeted therapies, or radium-223 for metastatic castrate-resistant and sensitive prostate cancer at the Princess Margaret Cancer Centre, Toronto, Canada. Six coders worked in pairs to review interview transcripts and conduct a thematic analysis. A consensus was reached through team discussions. Topics of interest included symptom experiences, the impact of symptoms on daily life, symptom management strategies, and suggestions for external support.
Thirty-six interviews were conducted with older adults (mean age: 76 years, 92% with metastatic castrate-resistant prostate cancer) who started chemotherapy (n = 11), androgen-axis targeted therapies (n = 19), or radium-223 (n = 6). The most common treatment-specific symptoms included: fatigue, pain, sleep disturbances, mood disturbances, and gastrointestinal symptoms. Four themes on the impact of symptoms on daily life emerged: resting more than usual, changes in mobility, changes in maintaining activities of daily living, and not feeling up to most things. It is important to note that participants who underwent chemotherapy have previously completed other lines of treatment and had more advanced disease, possibly contributing to higher prevalence of symptoms and greater impact on daily life. Four themes on symptom management strategies emerged: positive support systems, seeking help, interventions by healthcare providers, and self-management strategies. Suggestions for external support included building social support networks, improving health literacy, improving continuity of care, receiving support from healthcare providers, engaging in health-seeking behaviours, and addressing unmet supportive care needs.
Exploring symptom experiences of older men with metastatic prostate cancer provides valuable insights for developing supportive care programs and improving patient care.
探究老年男性在转移性前列腺癌治疗期间的症状体验,有助于临床医生识别未满足的支持性护理需求,若这些需求得到满足,则可改善毒性管理并提升患者的健康状况。先前针对老年晚期前列腺癌患者的定性研究聚焦于心理体验,而非整体症状体验。因此,本研究的目的是了解接受转移性前列腺癌治疗的老年男性的症状体验及支持性护理需求。
对年龄在65岁及以上、在加拿大多伦多玛格丽特公主癌症中心完成了首个化疗周期、雄激素轴靶向治疗或镭-223治疗的转移性去势抵抗性和敏感性前列腺癌老年患者进行了半结构式访谈。六位编码员两两合作,审查访谈记录并进行主题分析。通过团队讨论达成了共识。感兴趣的主题包括症状体验、症状对日常生活的影响、症状管理策略以及对外部支持的建议。
对开始化疗(n = 11)、雄激素轴靶向治疗(n = 19)或镭-223治疗(n = 6)的老年患者(平均年龄:76岁,92%为转移性去势抵抗性前列腺癌)进行了36次访谈。最常见的特定治疗症状包括:疲劳、疼痛、睡眠障碍、情绪障碍和胃肠道症状。出现了四个关于症状对日常生活影响的主题:比平时更多地休息、活动能力变化、维持日常生活活动的变化以及对大多数事情力不从心。需要注意的是,接受化疗的参与者此前已完成其他治疗方案且疾病更为晚期,这可能导致症状发生率更高且对日常生活的影响更大。出现了四个关于症状管理策略的主题:积极的支持系统、寻求帮助、医疗保健提供者的干预以及自我管理策略。对外部支持的建议包括建立社会支持网络、提高健康素养、改善护理连续性、获得医疗保健提供者的支持、采取寻求健康行为以及满足未满足的支持性护理需求。
探究转移性前列腺癌老年男性的症状体验,为制定支持性护理计划和改善患者护理提供了宝贵的见解。